Invitae Corporation (NVTA)

$2.495

-0.05 (-1.77%)
Rating:
Recommendation:
Neutral
Symbol NVTA
Price $2.495
Beta 1.905
Volume Avg. 8.81M
Market Cap 572.076M
Shares () -
52 Week Range 2.08-34.278
1y Target Est -
DCF Unlevered NVTA DCF ->
DCF Levered NVTA LDCF ->
ROE -15.59% Sell
ROA -9.47% Neutral
Operating Margin -
Debt / Equity 67.65% Buy
P/E -
P/B 0.20 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NVTA news


Dr. Sean George
Healthcare
Diagnostics & Research
New York Stock Exchange

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.